The U.S. Food and Drug Administration (FDA) had approved Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
Oncology
August 12,2024
0